Overview

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal